Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWBacterial type II fatty acid synthesis (FAS-II) is mediated by a series of enzymes, each of which may be targeted by potential antibiotics.1 Bischloroanthrabenzoxocinone (BABX) is an inhibitor of FAS-II, blocking fatty acid synthesis in S. aureus and E. coli with IC50 values of 11.4 and 35.3 µg/ml, respectively.2 It inhibits the growth of S. aureus and permeable E. coli strains with minimum inhibitory concentrations ranging from 0.2-0.4 µg/ml.2,3 BABX also displays binding to liver X receptors (LXRs), inhibiting agonist binding in an LXRα-scintillation proximity assay (IC50 = 10 µM).3
WARNING This product is not for human or veterinary use.
1. How bacterial pathogens eat host lipids: Implications for the development of fatty acid synthesis therapeutics. The Journal of Biological Chemisty 290(10), 5940-5946 (2015).
2. Determination of selectivity and efficacy of fatty acid synthesis inhibitors. The Journal of Biological Chemisty 280(2), 1669-1677 (2005).
3. Anthrabenzoxocinones from Streptomyces sp. as liver X receptor ligands and antibacterial agents. J. Nat. Prod. 68(9), 1437-1440 (2005).